相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 提供商:
合研生物
- 服务名称:
激酶抑制剂活性筛选
武汉合研生物医药科技有限公司坐落于光谷生物城,是一家专注于提供新药发现阶段的技术服务,以中小微新药研发企业为服务主体的创新型公司。合研生物拥有一支训练有素的药物研发技术团队,提供的服务覆盖虚拟筛选、酶学靶点筛选、抗肿瘤药物活性评价、细胞功能学检测、药理病理学服务等各项技术。我们的技术团队在分子生物学、细胞生物学、结构生物学等领域具有丰富的经验,通过酶水平、细胞水平测定等技术平台帮助客户进行化合物筛选及化合物特性、作用机制等研究。合研生物以高效、高性价比的专业服务帮助客户更快地达到目标,帮助客户推进药物发现的进程。
我们的服务
Kinase激酶
酶学研究一直是药物研发的重要组成部分。合研生物拥有丰富的酶学筛选经验,酶学实验涵盖300多种筛选模型,包括了常见的组蛋白去乙酰酶类,组蛋白去甲基化酶,酪氨酸激酶,丝氨酸激酶,甲基化转移酶,磷酸二酯酶,DNA修复酶,热休克蛋白,免疫相关蛋白等。根据样本量的大小提供灵活的项目实施安排计划,可提供96孔和384孔两种板型的筛选模式,加速您的药物研发进程。
| Kinase激酶 | |||
| E148 | ABL1 | ADP-Glo | 96/384 well |
| E149 | ABL1(E255K) | ADP-Glo | 96/384 well |
| E150 | ABL1(T315I) | ADP-Glo | 96/384 well |
| E151 | ABL1(Y253F) | ADP-Glo | 96/384 well |
| E152 | ACK | ADP-Glo | 96/384 well |
| E153 | AKT1 | ADP-Glo | 96/384 well |
| E154 | AKT2 | ADP-Glo | 96/384 well |
| E155 | AKT3 | ADP-Glo | 96/384 well |
| E156 | ALK2 | ADP-Glo | 96/384 well |
| E157 | ALK4 | ADP-Glo | 96/384 well |
| E158 | ALK6 | ADP-Glo | 96/384 well |
| E159 | AMAPK(A1/B1/G2) | ADP-Glo | 96/384 well |
| E160 | AMPK(A1/B1/G1) | ADP-Glo | 96/384 well |
| E161 | AMPK(A2/B1/G1) | ADP-Glo | 96/384 well |
| E162 | ASK1 | ADP-Glo | 96/384 well |
| E163 | Aurora A | ADP-Glo | 96/384 well |
| E164 | Aurora B | ADP-Glo | 96/384 well |
| E165 | AXL | ADP-Glo | 96/384 well |
| E166 | BRK | ADP-Glo | 96/384 well |
| E167 | BXM | ADP-Glo | 96/384 well |
| E168 | CAMK1γ | ADP-Glo | 96/384 well |
| E169 | CAMK2α | ADP-Glo | 96/384 well |
| E170 | CAMK2γ | ADP-Glo | 96/384 well |
| E171 | CAMKK1 | ADP-Glo | 96/384 well |
| E172 | CDC7/DBF4 | ADP-Glo | 96/384 well |
| E173 | CDK2/CyclinA2 | ADP-Glo | 96/384 well |
| E174 | CDK2/CyclinE1 | ADP-Glo | 96/384 well |
| E175 | CDK3/cyclinE1 | ADP-Glo | 96/384 well |
| E176 | CDK5/p25 | ADP-Glo | 96/384 well |
| E177 | CDK5/p35 | ADP-Glo | 96/384 well |
| E178 | CDK6/CyclinD3 | ADP-Glo | 96/384 well |
| E179 | CDK9/Cyclink | ADP-Glo | 96/384 well |
| E180 | CHK1 | ADP-Glo | 96/384 well |
| E181 | CHK2 | ADP-Glo | 96/384 well |
| E182 | CK1a1 | ADP-Glo | 96/384 well |
| E183 | CK1γ1 | ADP-Glo | 96/384 well |
| E184 | CK1ε | ADP-Glo | 96/384 well |
| E185 | CK2α1 | ADP-Glo | 96/384 well |
| E186 | c-KIT | ADP-Glo | 96/384 well |
| E187 | CLK1 | ADP-Glo | 96/384 well |
| E188 | CLK3 | ADP-Glo | 96/384 well |
| E189 | c-MER | ADP-Glo | 96/384 well |
| E190 | CSK | ADP-Glo | 96/384 well |
| E191 | DAPK1 | ADP-Glo | 96/384 well |
| E192 | DDR2 | ADP-Glo | 96/384 well |
| E193 | DNA-PK | ADP-Glo | 96/384 well |
| E194 | DYRK2 | ADP-Glo | 96/384 well |
| E195 | EGFR | ADP-Glo | 96/384 well |
| E196 | EGFR(L858R) | ADP-Glo | 96/384 well |
| E197 | EGFR(L861Q) | ADP-Glo | 96/384 well |
| E198 | EGFR(T790,L858R) | ADP-Glo | 96/384 well |
| E199 | EGFR(T790M) | ADP-Glo | 96/384 well |
| E200 | EIF2AK2 | ADP-Glo | 96/384 well |
| E201 | EPHA1 | ADP-Glo | 96/384 well |
| E202 | ERK1 | ADP-Glo | 96/384 well |
| E203 | ERK2 | ADP-Glo | 96/384 well |
| E204 | FAK | ADP-Glo | 96/384 well |
| E205 | FES | ADP-Glo | 96/384 well |
| E206 | FGFR1 | ADP-Glo | 96/384 well |
| E207 | FGFR2 | ADP-Glo | 96/384 well |
| E208 | FGFR3(K650E) | ADP-Glo | 96/384 well |
| E209 | FGFR4 | ADP-Glo | 96/384 well |
| E210 | FLT1 | ADP-Glo | 96/384 well |
| E211 | FLT3 | ADP-Glo | 96/384 well |
| E212 | FLT3(D835Y) | ADP-Glo | 96/384 well |
| E213 | FMS | ADP-Glo | 96/384 well |
| E214 | FYN A | ADP-Glo | 96/384 well |
| E215 | GRK5 | ADP-Glo | 96/384 well |
| E216 | GSK3α | ADP-Glo | 96/384 well |
| E217 | GSK3β | ADP-Glo | 96/384 well |
| E218 | HER2 | ADP-Glo | 96/384 well |
| E219 | HER4 | ADP-Glo | 96/384 well |
| E220 | HIPK1 | ADP-Glo | 96/384 well |
| E221 | HPK1 | ADP-Glo | 96/384 well |
| E222 | IGF1R | ADP-Glo | 96/384 well |
| E223 | IKKß | ADP-Glo | 96/384 well |
| E224 | IKKα | ADP-Glo | 96/384 well |
| E225 | InsR | ADP-Glo | 96/384 well |
| E226 | IRAK4 | ADP-Glo | 96/384 well |
| E227 | ITK | ADP-Glo | 96/384 well |
| E228 | JAK3 | ADP-Glo | 96/384 well |
| E229 | JNK1 | ADP-Glo | 96/384 well |
| E230 | JNK3 | ADP-Glo | 96/384 well |
| E231 | KDR | ADP-Glo | 96/384 well |
| E232 | KHS1 | ADP-Glo | 96/384 well |
| E233 | LCK | ADP-Glo | 96/384 well |
| E234 | Lipid kinase | ADP-Glo | 96/384 well |
| E235 | LRRK2 | ADP-Glo | 96/384 well |
| E236 | LYN B | ADP-Glo | 96/384 well |
| E237 | MAPKAPK2 | ADP-Glo | 96/384 well |
| E238 | MAPKAPK3 | ADP-Glo | 96/384 well |
| E239 | MAPKAPK5 | ADP-Glo | 96/384 well |
| E240 | MARK1 | ADP-Glo | 96/384 well |
| E241 | MELK | ADP-Glo | 96/384 well |
| E242 | MET | ADP-Glo | 96/384 well |
| E243 | MET(M1250T) | ADP-Glo | 96/384 well |
| E244 | MINK1 | ADP-Glo | 96/384 well |
| E245 | MLCK | ADP-Glo | 96/384 well |
| E246 | MLK1 | ADP-Glo | 96/384 well |
| E247 | MLK2 | ADP-Glo | 96/384 well |
| E248 | MRCKa | ADP-Glo | 96/384 well |
| E249 | MSK1 | ADP-Glo | 96/384 well |
| E250 | MSK2 | ADP-Glo | 96/384 well |
| E251 | MST1 | ADP-Glo | 96/384 well |
| E252 | MYO3β | ADP-Glo | 96/384 well |
| E253 | Name | ADP-Glo | 96/384 well |
| E254 | NEK2 | ADP-Glo | 96/384 well |
| E255 | NEK3 | ADP-Glo | 96/384 well |
| E256 | NIK | ADP-Glo | 96/384 well |
| E257 | NUAK2 | ADP-Glo | 96/384 well |
| E258 | p38B | ADP-Glo | 96/384 well |
| E259 | p38α | ADP-Glo | 96/384 well |
| E260 | p38γ | ADP-Glo | 96/384 well |
| E261 | P38δ | ADP-Glo | 96/384 well |
| E262 | p70S6K | ADP-Glo | 96/384 well |
| E263 | p70S6Kb | ADP-Glo | 96/384 well |
| E264 | PAK1/CDC42 | ADP-Glo | 96/384 well |
| E265 | PAK3 | ADP-Glo | 96/384 well |
| E266 | PAK4 | ADP-Glo | 96/384 well |
| E267 | PASK | ADP-Glo | 96/384 well |
| E268 | PDGFRa(D842V) | ADP-Glo | 96/384 well |
| E269 | PDGFRa(T674I) | ADP-Glo | 96/384 well |
| E270 | PDGFRα | ADP-Glo | 96/384 well |
| E271 | PDGFRβ | ADP-Glo | 96/384 well |
| E272 | PDK1 | ADP-Glo | 96/384 well |
| E273 | PI3K Lipid kinases | ADP-Glo | 96/384 well |
| E274 | PI3K-Glo | ADP-Glo | 96/384 well |
| E275 | PIM1 | ADP-Glo | 96/384 well |
| E276 | PIM2 | ADP-Glo | 96/384 well |
| E277 | PKA | ADP-Glo | 96/384 well |
| E278 | PKC | ADP-Glo | 96/384 well |
| E279 | PKCß1 | ADP-Glo | 96/384 well |
| E280 | PKCα | ADP-Glo | 96/384 well |
| E281 | PKCβII | ADP-Glo | 96/384 well |
| E282 | PKCγ | ADP-Glo | 96/384 well |
| E283 | PKCδ | ADP-Glo | 96/384 well |
| E284 | PKCε | ADP-Glo | 96/384 well |
| E285 | PKCζ | ADP-Glo | 96/384 well |
| E286 | PKCθ | ADP-Glo | 96/384 well |
| E287 | PKCι | ADP-Glo | 96/384 well |
| E288 | PKCμ | ADP-Glo | 96/384 well |
| E289 | PKD2 | ADP-Glo | 96/384 well |
| E290 | PLK1 | ADP-Glo | 96/384 well |
| E291 | PRKG1 | ADP-Glo | 96/384 well |
| E292 | PYK2 | ADP-Glo | 96/384 well |
| E293 | RET | ADP-Glo | 96/384 well |
| E294 | RET(V804L) | ADP-Glo | 96/384 well |
| E295 | RET(Y791F) | ADP-Glo | 96/384 well |
| E296 | RIPK2 | ADP-Glo | 96/384 well |
| E297 | ROCK1 | ADP-Glo | 96/384 well |
| E298 | ROCK2 | ADP-Glo | 96/384 well |
| E299 | RON | ADP-Glo | 96/384 well |
| E300 | RSK1 | ADP-Glo | 96/384 well |
| E301 | SGK1 | ADP-Glo | 96/384 well |
| E302 | SIK | ADP-Glo | 96/384 well |
| E303 | SLK | ADP-Glo | 96/384 well |
| E304 | SRC | ADP-Glo | 96/384 well |
| E305 | STK33 | ADP-Glo | 96/384 well |
| E306 | SYK | ADP-Glo | 96/384 well |
| E307 | TAK1-TAB1 | ADP-Glo | 96/384 well |
| E308 | TAOK1 | ADP-Glo | 96/384 well |
| E309 | TBK1 | ADP-Glo | 96/384 well |
| E310 | TGFbR1 | ADP-Glo | 96/384 well |
| E311 | TGFβR2 | ADP-Glo | 96/384 well |
| E312 | TNIK | ADP-Glo | 96/384 well |
| E313 | TOPK | ADP-Glo | 96/384 well |
| E314 | TRKA | ADP-Glo | 96/384 well |
| E315 | TRKB | ADP-Glo | 96/384 well |
| E316 | ULK1 | ADP-Glo | 96/384 well |
| E317 | VRK2 | ADP-Glo | 96/384 well |
| E318 | WNK1 | ADP-Glo | 96/384 well |
| E319 | ZAK | ADP-Glo | 96/384 well |
| E320 | ZAP70 | ADP-Glo | 96/384 well |
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验3 篇 Nature 连发,解决世纪难题,周期蛋白的毁灭调控蕴含癌症患者的新生
在 cyclin D 上,被泛素化标记的 cyclin D 将会被蛋白酶体降解。此外研究还发现,AMBRA1 缺失会导致 cyclin D 和 MYC 蛋白水平升高。cyclin D 与 CDK4/6 结合,使 RB1 蛋白磷酸化。磷酸化 RB1 释放 E2F 转录因子来驱动细胞周期进程所需基因的表达。在 AMBRA1 缺失的细胞中,cyclin D 也能与 CDK2 激酶形成复合物,使癌细胞能够抵抗 CDK4/6 抑制剂的治疗。高水平的 cyclin D 会促进细胞增殖,从而导致 DNA 损伤、复制应激
Cell Metabo: 另辟蹊径!武汉大学李红良等团队合作发现 2 型糖尿病治疗新靶点
异生调节网络中起着关键作用,并可能成为 T2D 的潜在治疗靶点。图片来源: Cell Metabolism 研究内容 1. Kinome(人激酶组)筛选锁定 NLK 是 HGP 关键抑制因子 候选激酶亚群中 NLK 对 Pck1 和 G6pc(糖异生关键酶)启动子活性均表现出明显的抑制作用。在小鼠原代肝细胞中,过表达 NLK 可以显著抑制 Pck1 和 G6pc 基因的 mRNA 和蛋白水平,而过表达 NLK 功能突变体(K167M)则未能发挥抑制功能。实验结果表明,NLK 通过激酶活性抑制肝糖
Nat Chem Biol:精氨酸甲基化转移酶调控三阴性乳腺癌的内源免疫新机制
inhibition triggers the viral mimicry response in Triple Negative Breast Cancer 的研究论文,揭示了精氨酸甲基化转移酶调控内源免疫的新机制,为三阴性乳腺癌的免疫治疗提供了新的策略。 作者首先利用表观遗传小分子抑制剂对三阴性乳腺癌进行了系统筛选,鉴定出精氨酸甲基化转移酶可能是新的治疗靶点。并结合化学生物学、细胞生物学和生物信息学的方法对其作用机制进行了深入探讨,发现靶向精氨酸甲基化转移酶可调控细胞内的可变剪接,造成大量内含子滞留,滞留









